BR112023005214A2 - Compostos inovadores - Google Patents
Compostos inovadoresInfo
- Publication number
- BR112023005214A2 BR112023005214A2 BR112023005214A BR112023005214A BR112023005214A2 BR 112023005214 A2 BR112023005214 A2 BR 112023005214A2 BR 112023005214 A BR112023005214 A BR 112023005214A BR 112023005214 A BR112023005214 A BR 112023005214A BR 112023005214 A2 BR112023005214 A2 BR 112023005214A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- innovative
- innovative compounds
- nlrp3 inflammasome
- medicaments
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTOS INOVADORES. A presente invenção refere-se a compostos inovadores para uso como inibidores da produção de inflamassoma de NLRP3, em que tais compostos são conforme definidos pelos compostos da fórmula (I) e em que os números inteiros R1, R2 e R3 são definidos na descrição, e em que os compostos podem ser úteis como medicamentos, por exemplo, para uso no tratamento de uma doença ou transtorno que é associado à atividade de inflamassoma de NLRP3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382845.4A EP3974415A1 (en) | 2020-09-24 | 2020-09-24 | Nlrp3 modulators |
PCT/EP2021/076164 WO2022063876A1 (en) | 2020-09-24 | 2021-09-23 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023005214A2 true BR112023005214A2 (pt) | 2023-04-25 |
Family
ID=72709314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023005214A BR112023005214A2 (pt) | 2020-09-24 | 2021-09-23 | Compostos inovadores |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230391756A1 (pt) |
EP (2) | EP3974415A1 (pt) |
JP (1) | JP2023542231A (pt) |
KR (1) | KR20230074199A (pt) |
CN (1) | CN116323585A (pt) |
AR (1) | AR123582A1 (pt) |
AU (1) | AU2021346843A1 (pt) |
BR (1) | BR112023005214A2 (pt) |
CA (1) | CA3192262A1 (pt) |
MX (1) | MX2023003458A (pt) |
TW (1) | TW202229244A (pt) |
UY (1) | UY39434A (pt) |
WO (1) | WO2022063876A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024057013A1 (en) | 2022-09-12 | 2024-03-21 | Exscientia Ai Limited | Nlrp3 modulators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201710851D0 (en) * | 2017-07-06 | 2017-08-23 | Galápagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
EP3697758B1 (en) | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
US20220098188A1 (en) | 2018-08-17 | 2022-03-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors |
-
2020
- 2020-09-24 EP EP20382845.4A patent/EP3974415A1/en not_active Ceased
-
2021
- 2021-09-23 AR ARP210102642A patent/AR123582A1/es unknown
- 2021-09-23 KR KR1020237013218A patent/KR20230074199A/ko active Search and Examination
- 2021-09-23 BR BR112023005214A patent/BR112023005214A2/pt unknown
- 2021-09-23 MX MX2023003458A patent/MX2023003458A/es unknown
- 2021-09-23 UY UY0001039434A patent/UY39434A/es unknown
- 2021-09-23 TW TW110135274A patent/TW202229244A/zh unknown
- 2021-09-23 CN CN202180064525.XA patent/CN116323585A/zh active Pending
- 2021-09-23 JP JP2023518741A patent/JP2023542231A/ja active Pending
- 2021-09-23 AU AU2021346843A patent/AU2021346843A1/en active Pending
- 2021-09-23 WO PCT/EP2021/076164 patent/WO2022063876A1/en unknown
- 2021-09-23 CA CA3192262A patent/CA3192262A1/en active Pending
- 2021-09-23 US US18/245,765 patent/US20230391756A1/en active Pending
- 2021-09-23 EP EP21777807.5A patent/EP4217346A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3192262A1 (en) | 2022-03-31 |
EP3974415A1 (en) | 2022-03-30 |
AU2021346843A9 (en) | 2024-02-08 |
CN116323585A (zh) | 2023-06-23 |
WO2022063876A1 (en) | 2022-03-31 |
US20230391756A1 (en) | 2023-12-07 |
AU2021346843A1 (en) | 2023-06-08 |
MX2023003458A (es) | 2023-04-19 |
EP4217346A1 (en) | 2023-08-02 |
JP2023542231A (ja) | 2023-10-05 |
UY39434A (es) | 2022-03-31 |
TW202229244A (zh) | 2022-08-01 |
KR20230074199A (ko) | 2023-05-26 |
AR123582A1 (es) | 2022-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022023271A2 (pt) | Compostos | |
BR112022020776A2 (pt) | Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3 | |
BR112022020798A2 (pt) | Compostos tricíclicos como inibidores de nlrp3 | |
BR112022021881A2 (pt) | Novos compostos de triazinoindol | |
BR112022020807A2 (pt) | Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 | |
BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
BR112019007039A2 (pt) | pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística | |
BR112022019057A2 (pt) | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
BR112022012195A2 (pt) | Derivados de piperidina bicíclico substituídos úteis como ativadores de células t | |
BRPI0513086A (pt) | 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos | |
BR112013003097A2 (pt) | 6-cicloalquil-pirazolopirimidemonas para o tratamento de distúrbio de cns | |
BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
BR112012030024A2 (pt) | compostos, processo para a preparação de um composto, medicamento | |
BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
BR112016005881A2 (pt) | composto, composição farmacêutica e uso do composto | |
BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
BR112022012220A2 (pt) | Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t | |
BR112022024045A2 (pt) | Moduladores il-17a | |
BR112023022451A2 (pt) | Composto triazina substituído | |
BR112023019030A2 (pt) | Derivados de fósforo como inibidores de sos1 | |
BR112022023983A2 (pt) | Compostos terapêuticos | |
BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) |